The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1631
ISSUE1631
August 23, 2021
Finerenone (Kerendia) for Chronic Kidney Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Finerenone (Kerendia) for Chronic Kidney Disease
August 23, 2021 (Issue: 1631)
Finerenone (Kerendia – Bayer), an oral nonsteroidal
mineralocorticoid receptor antagonist (MRA), has
been approved by the FDA to reduce the risk of
sustained eGFR decline, end-stage renal disease,
nonfatal MI, hospitalization for heart failure...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.